Avena-Woods Carmela, Hilas Olga
St. John's University College of Pharmacy and Health Sciences, Queens, NY, USA.
Consult Pharm. 2012 Dec;27(12):868-70. doi: 10.4140/TCP.n.2012.868.
Mirtazapine is an antidepressant approved for the treatment of major depressive disorder. It has been reported to also stimulate appetite and/or increase body weight, which may be beneficial in certain patient populations such as the elderly. To evaluate the use of mirtazapine and other antidepressants in underweight older adults, a retrospective chart review of patients (60 years of age or older and with a body mass index < 22 kg/m2) who were prescribed an antidepressant during hospitalization was conducted over a six-month period at a large university teaching hospital. Results demonstrated that underweight older patients were more likely to receive mirtazapine than any other antidepressant, prompting a systematic literature review to assess its potential role in appetite stimulation and weight gain. In addition, educational inservice training for health care professionals within the institution was provided to discuss the management of weight loss and appetite suppression in the elderly as well as the potential benefits and risks of antidepressant therapy in older adults.
米氮平是一种被批准用于治疗重度抑郁症的抗抑郁药。据报道，它还能刺激食欲和/或增加体重，这对某些患者群体（如老年人）可能有益。为了评估米氮平及其他抗抑郁药在体重过轻的老年人中的使用情况，在一所大型大学教学医院进行了为期六个月的回顾性病历审查，对象为住院期间开具了抗抑郁药的患者（年龄60岁及以上，体重指数<22 kg/m²）。结果表明，体重过轻的老年患者比其他任何抗抑郁药更有可能接受米氮平治疗，这促使进行系统的文献综述，以评估其在刺激食欲和体重增加方面的潜在作用。此外，还为该机构内的医护人员提供了在职教育培训，以讨论老年人体重减轻和食欲抑制的管理，以及老年人抗抑郁治疗的潜在益处和风险。
